Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Breast Cancer

  Free Subscription

Articles published in Int J Oncol

Retrieve available abstracts of 116 articles:
HTML format

Single Articles

    May 2021
  1. MU H, Zhang W, Qiu Y, Tao T, et al
    miRNAs as potential markers for breast cancer and regulators of tumorigenesis and progression (Review).
    Int J Oncol. 2021;58.
    PubMed     Abstract available

  2. KANG J, Zhong Y, Tian W, Li J, et al
    A novel anthraquinonequinazoline hybrid 7B blocks breast cancer metastasis and EMT via targeting EGFR and Rac1.
    Int J Oncol. 2021;58.
    PubMed     Abstract available

    April 2021
  3. WU D, Jia H, Zhang Z, Li S, et al
    Circ_0000511 accelerates the proliferation, migration and invasion, and restrains the apoptosis of breast cancer cells through the miR326/TAZ axis.
    Int J Oncol. 2021;58:1.
    PubMed     Abstract available

    March 2021
  4. HUERTA-REYES M, Aguilar-Rojas A
    Threedimensional models to study breast cancer (Review).
    Int J Oncol. 2021;58:331-343.
    PubMed     Abstract available

    January 2021
  5. LI W, Liu C, Zhao C, Zhai L, et al
    [Corrigendum] Downregulation of beta3 integrin by miR-30a-5p modulates cell adhesion and invasion by interrupting Erk/Ets1 network in triple-negative breast cancer.
    Int J Oncol. 2021 Jan 11. doi: 10.3892/ijo.2021.5169.
    PubMed     Abstract available

    December 2020
  6. WON KA, Spruck C
    Triplenegative breast cancer therapy: Current and future perspectives (Review).
    Int J Oncol. 2020;57:1245-1261.
    PubMed     Abstract available

  7. LV S, Xu W, Zhang Y, Zhang J, et al
    NUF2 as an anticancer therapeutic target and prognostic factor in breast cancer.
    Int J Oncol. 2020;57:1358-1367.
    PubMed     Abstract available

    November 2020
  8. JIA H, Wu D, Zhang Z, Li S, et al
    Regulatory effect of the MAFGAS1/miR1505p/MYB axis on the proliferation and migration of breast cancer cells.
    Int J Oncol. 2020 Nov 20. doi: 10.3892/ijo.2020.5150.
    PubMed     Abstract available

    September 2020
  9. MARTIN CJ, Moorehead RA
    Polycomb repressor complex 2 function in breast cancer (Review).
    Int J Oncol. 2020 Sep 17. doi: 10.3892/ijo.2020.5122.
    PubMed     Abstract available

    August 2020
  10. YANG WJ, Zhang GL, Cao KX, Liu XN, et al
    Heparanase from triplenegative breast cancer and platelets acts as an enhancer of metastasis.
    Int J Oncol. 2020 Aug 27. doi: 10.3892/ijo.2020.5115.
    PubMed     Abstract available

  11. LIU W, Xiong X, Chen W, Li X, et al
    High expression of FUSE binding protein 1 in breast cancer stimulates cell proliferation and diminishes drug sensitivity.
    Int J Oncol. 2020;57:488-499.
    PubMed     Abstract available

  12. MOHAMMED F, Rashid-Doubell F, Taha S, Cassidy S, et al
    Effects of curcumin complexes on MDAMB231 breast cancer cell proliferation.
    Int J Oncol. 2020;57:445-455.
    PubMed     Abstract available

    May 2020
  13. NAKAMURA M, Takano A, Thang PM, Tsevegjav B, et al
    Characterization of KIF20A as a prognostic biomarker and therapeutic target for different subtypes of breast cancer.
    Int J Oncol. 2020 May 7. doi: 10.3892/ijo.2020.5060.
    PubMed     Abstract available

  14. CHEN F, Zhang Z, Yu Y, Liu Q, et al
    HSulf1 and palbociclib exert synergistic antitumor effects on RBpositive triplenegative breast cancer.
    Int J Oncol. 2020 May 4. doi: 10.3892/ijo.2020.5057.
    PubMed     Abstract available

    April 2020
  15. REES JS, Cheung LCC, Hamaia SW, Davies G, et al
    Identification of the cismolecular neighbours of the immune checkpoint protein B7H4 in the breast cancer cellline SKBR3 by proteomic proximity labelling.
    Int J Oncol. 2020 Apr 3. doi: 10.3892/ijo.2020.5037.
    PubMed     Abstract available

    March 2020
  16. NETSIRISAWAN P, Chokchaichamnankit D, Saharat K, Srisomsap C, et al
    Quantitative proteomic analysis of the association between decreasing OGlcNAcylation and metastasis in MCF7 breast cancer cells.
    Int J Oncol. 2020 Mar 20. doi: 10.3892/ijo.2020.5022.
    PubMed     Abstract available

  17. KIM OH, Lee JH, Mah S, Park SY, et al
    HS146, a novel phosphoinositide 3kinase alpha inhibitor, induces the apoptosis and inhibits the metastatic ability of human breast cancer cells.
    Int J Oncol. 2020 Mar 19. doi: 10.3892/ijo.2020.5018.
    PubMed     Abstract available

  18. XIONG H, Shen J, Chen Z, Yang J, et al
    H19/let7/Lin28 ceRNA network mediates autophagy inhibiting epithelialmesenchymal transition in breast cancer.
    Int J Oncol. 2020;56:794-806.
    PubMed     Abstract available

  19. ZHANG F, Ma Y, Xu L, Xu H, et al
    Long noncoding RNA profile revealed by microarray indicates that lncCUEDC1 serves a negative regulatory role in breast cancer stem cells.
    Int J Oncol. 2020;56:807-820.
    PubMed     Abstract available

    February 2020
  20. HU J, Ji C, Hua K, Wang X, et al
    Hsa_circ_0091074 regulates TAZ expression via microRNA1297 in triple negative breast cancer cells.
    Int J Oncol. 2020 Feb 25. doi: 10.3892/ijo.2020.5000.
    PubMed     Abstract available

  21. ZHANG KJ, Hu Y, Luo N, Li X, et al
    miR5745p attenuates proliferation, migration and EMT in triplenegative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.
    Int J Oncol. 2020 Feb 20. doi: 10.3892/ijo.2020.4995.
    PubMed     Abstract available

  22. WANG X, Fang Y, Sun W, Xu Z, et al
    Endocrinotherapy resistance of prostate and breast cancer: Importance of the NFkappaB pathway (Review).
    Int J Oncol. 2020 Feb 19. doi: 10.3892/ijo.2020.4990.
    PubMed     Abstract available

  23. CHEN R, Guo S, Yang C, Sun L, et al
    Although cMYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ERpositive breast cancer.
    Int J Oncol. 2020 Feb 14. doi: 10.3892/ijo.2020.4987.
    PubMed     Abstract available

  24. AHMAD AE, Khajah MA, Khushaish S, Luqmani YA, et al
    Aquaporin expression in breast cancer and their involvement in bleb formation, cell motility and invasion in endocrine resistant variant cells.
    Int J Oncol. 2020 Feb 5. doi: 10.3892/ijo.2020.4976.
    PubMed     Abstract available

  25. GALLARDO M, Kemmerling U, Aguayo F, Bleak TC, et al
    Curcumin rescues breast cells from epithelialmesenchymal transition and invasion induced by antimiR34a.
    Int J Oncol. 2020;56:480-493.
    PubMed     Abstract available

    January 2020
  26. POOFERY J, Sripanidkulchai B, Banjerdpongchai R
    Extracts of Bridelia ovata and Croton oblongifolius induce apoptosis in human MDAMB231 breast cancer cells via oxidative stress and mitochondrial pathways.
    Int J Oncol. 2020 Jan 31. doi: 10.3892/ijo.2020.4973.
    PubMed     Abstract available

  27. LEE KS, Nam GS, Baek J, Kim S, et al
    Inhibition of TPAinduced metastatic potential by morin hydrate in MCF7 human breast cancer cells via the Akt/GSK3beta/cFos signaling pathway.
    Int J Oncol. 2020 Jan 2. doi: 10.3892/ijo.2020.4954.
    PubMed     Abstract available

    December 2019
  28. LI Z, Zhang X, Hou C, Zhou Y, et al
    Comprehensive identification and characterization of somatic copy number alterations in triplenegative breast cancer.
    Int J Oncol. 2019 Dec 23. doi: 10.3892/ijo.2019.4950.
    PubMed     Abstract available

  29. KIMURA R, Yoshimaru T, Matsushita Y, Matsuo T, et al
    The GALNT6LGALS3BP axis promotes breast cancer cell growth.
    Int J Oncol. 2019 Dec 13. doi: 10.3892/ijo.2019.4941.
    PubMed     Abstract available

  30. YUAN M, Xie F, Xia X, Zhong K, et al
    UNC5Cknockdown enhances the growth and metastasis of breast cancer cells by potentiating the integrin alpha6/beta4 signaling pathway.
    Int J Oncol. 2019 Dec 2. doi: 10.3892/ijo.2019.4931.
    PubMed     Abstract available

    November 2019
  31. RITTER A, Hirschfeld M, Berner K, Rucker G, et al
    Circulating noncoding RNAbiomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
    Int J Oncol. 2019 Nov 25. doi: 10.3892/ijo.2019.4920.
    PubMed     Abstract available

  32. DITTMER A, Lange T, Leyh B, Dittmer J, et al
    Protein and growthmodulatory effects of carcinomaassociated fibroblasts on breast cancer cells: Role of interleukin6.
    Int J Oncol. 2019 Nov 22. doi: 10.3892/ijo.2019.4918.
    PubMed     Abstract available

    October 2019
  33. KONINGS K, Belmans N, Vermeesen R, Baselet B, et al
    Targeting the Hedgehog pathway in combination with Xray or carbon ion radiation decreases migration of MCF7 breast cancer cells.
    Int J Oncol. 2019 Oct 18. doi: 10.3892/ijo.2019.4901.
    PubMed     Abstract available

  34. MAGIC Z, Sandstrom J, Perez-Tenorio G
    EphrinB2 inhibits cell proliferation and motility in vitro and predicts longer metastasisfree survival in breast cancer.
    Int J Oncol. 2019 Oct 4. doi: 10.3892/ijo.2019.4892.
    PubMed     Abstract available

  35. THOMAS PB, Seim I, Jeffery PL, Gahete MD, et al
    The long non-coding RNA GHSROS facilitates breast cancer cell migration and orthotopic xenograft tumour growth.
    Int J Oncol. 2019 Oct 4. doi: 10.3892/ijo.2019.4891.
    PubMed     Abstract available

    September 2019
  36. WANG S, Huang M, Wang Z, Wang W, et al
    MicroRNA133b targets TGFbeta receptor I to inhibit TGFbetainduced epithelialtomesenchymal transition and metastasis by suppressing the TGFbeta/SMAD pathway in breast cancer.
    Int J Oncol. 2019 Sep 18. doi: 10.3892/ijo.2019.4879.
    PubMed     Abstract available

  37. FENG L, Huang S, An G, Wang G, et al
    Identification of new cancer stem cell markers and signaling pathways in HER2positive breast cancer by transcriptome sequencing.
    Int J Oncol. 2019 Sep 12. doi: 10.3892/ijo.2019.4876.
    PubMed     Abstract available

  38. XIONG Y, Liu Z, Li Z, Wang S, et al
    Long noncoding RNA nuclear paraspeckle assembly transcript 1 interacts with microRNA107 to modulate breast cancer growth and metastasis by targeting carnitine palmitoyltransferase1.
    Int J Oncol. 2019 Sep 4. doi: 10.3892/ijo.2019.4869.
    PubMed     Abstract available

    July 2019
  39. PANG Y, Wu J, Li X, Wang C, et al
    NEAT1/miR124/STAT3 feedback loop promotes breast cancer progression.
    Int J Oncol. 2019 Jul 15. doi: 10.3892/ijo.2019.4841.
    PubMed     Abstract available

  40. YANG C, Yu H, Chen R, Tao K, et al
    CXCL1 stimulates migration and invasion in ERnegative breast cancer cells via activation of the ERK/MMP2/9 signaling axis.
    Int J Oncol. 2019 Jul 15. doi: 10.3892/ijo.2019.4840.
    PubMed     Abstract available

    June 2019
  41. WANG L, Shi H, Liu Y, Zhang W, et al
    Cystathioninegammalyase promotes the metastasis of breast cancer via the VEGF signaling pathway.
    Int J Oncol. 2019 Jun 6. doi: 10.3892/ijo.2019.4823.
    PubMed     Abstract available

  42. LI P, Liu Y, Liu W, Li G, et al
    IR-783 inhibits breast cancer cell proliferation and migration by inducing mitochondrial fission.
    Int J Oncol. 2019 Jun 6. doi: 10.3892/ijo.2019.4821.
    PubMed     Abstract available

  43. NAKAYAMA Y, Mimura K, Tamaki T, Shiraishi K, et al
    PhosphoSTAT1 expression as a potential biomarker for antiPD1/antiPDL1 immunotherapy for breast cancer.
    Int J Oncol. 2019;54:2030-2038.
    PubMed     Abstract available

  44. DING Y, He J, Huang J, Yu T, et al
    Harmine induces anticancer activity in breast cancer cells via targeting TAZ.
    Int J Oncol. 2019;54:1995-2004.
    PubMed     Abstract available

  45. CHENG S, Castillo V, Sliva D
    CDC20 associated with cancer metastasis and novel mushroomderived CDC20 inhibitors with antimetastatic activity.
    Int J Oncol. 2019;54:2250-2256.
    PubMed     Abstract available

    March 2019
  46. ZHOU X, Li T, Chen Y, Zhang N, et al
    Mesenchymal stem cellderived extracellular vesicles promote the in vitro proliferation and migration of breast cancer cells through the activation of the ERK pathway.
    Int J Oncol. 2019 Mar 13. doi: 10.3892/ijo.2019.4747.
    PubMed     Abstract available

    February 2019
  47. SHAO G, Wang M, Fan X, Zhong L, et al
    lncRNA CASC9 positively regulates CHK1 to promote breast cancer cell proliferation and survival through sponging the miR195/497 cluster.
    Int J Oncol. 2019 Feb 28. doi: 10.3892/ijo.2019.4734.
    PubMed     Abstract available

  48. AHN EH, Yang H, Hsieh CY, Sun W, et al
    Evaluation of chemotherapeutic and cancer-protective properties of sphingosine and C2-ceramide in a human breast stem cell derived carcinogenesis model.
    Int J Oncol. 2019;54:655-664.
    PubMed     Abstract available

  49. SEOK J, Yoon SH, Lee SH, Jung JH, et al
    The oncometabolite d2hydroxyglutarate induces angiogenic activity through the vascular endothelial growth factor receptor 2 signaling pathway.
    Int J Oncol. 2019;54:753-763.
    PubMed     Abstract available

    January 2019
  50. GURDAL H, Tuglu MM, Bostanabad SY, Dalkilic B, et al
    Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triplenegative breast cancer cell lines.
    Int J Oncol. 2019 Jan 28. doi: 10.3892/ijo.2019.4697.
    PubMed     Abstract available

  51. CHEN P, Yue X, Xiong H, Lu X, et al
    RBM3 upregulates ARPC2 by binding the 3'UTR and contributes to breast cancer progression.
    Int J Oncol. 2019 Jan 28. doi: 10.3892/ijo.2019.4698.
    PubMed     Abstract available

  52. SELMIN OI, Donovan MG, Skovan B, Paine-Murieta GD, et al
    Arsenicinduced BRCA1 CpG promoter methylation is associated with the downregulation of ERalpha and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts.
    Int J Oncol. 2019 Jan 15. doi: 10.3892/ijo.2019.4687.
    PubMed     Abstract available

  53. LI Z, Yu D, Li H, Lv Y, et al
    Long noncoding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway.
    Int J Oncol. 2019 Jan 8. doi: 10.3892/ijo.2019.4679.
    PubMed     Abstract available

  54. HANDA T, Katayama A, Yokobori T, Yamane A, et al
    Carboxypeptidase A4 accumulation is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer.
    Int J Oncol. 2019 Jan 4. doi: 10.3892/ijo.2019.4675.
    PubMed     Abstract available

  55. JIANG M, Qiu N, Xia H, Liang H, et al
    Long noncoding RNA FOXD2AS1/miR1505p/PFN2 axis regulates breast cancer malignancy and tumorigenesis.
    Int J Oncol. 2019 Jan 3. doi: 10.3892/ijo.2019.4671.
    PubMed     Abstract available

    December 2018
  56. LUPICKI K, Elifio-Esposito S, Fonseca AS, Weber SH, et al
    Patterns of copy number alterations in primary breast tumors of South African patients and their impact on functional cellular pathways.
    Int J Oncol. 2018;53:2745-2757.
    PubMed     Abstract available

    November 2018
  57. JIN H, Ko YS, Kim HJ
    P2Y2R-mediated inflammasome activation is involved in tumor progression in breast cancer cells and in radiotherapy-resistant breast cancer.
    Int J Oncol. 2018;53:1953-1966.
    PubMed     Abstract available

  58. PIZON M, Schott DS, Pachmann U, Pachmann K, et al
    B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients.
    Int J Oncol. 2018;53:2289-2299.
    PubMed     Abstract available

  59. WANG ZF, Sun WY, Yu DH, Zhao Y, et al
    Rotundic acid enhances the impact of radiological toxicity on MCF-7 cells through the ATM/p53 pathway.
    Int J Oncol. 2018;53:2269-2277.
    PubMed     Abstract available

    October 2018
  60. KIM SK, Kim K, Ryu JW, Ryu TY, et al
    The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer.
    Int J Oncol. 2018 Oct 26. doi: 10.3892/ijo.2018.4608.
    PubMed     Abstract available

  61. FURLAN A, Vercamer C, Heliot L, Wernert N, et al
    Ets-1 drives breast cancer cell angiogenic potential and interactions between breast cancer and endothelial cells.
    Int J Oncol. 2018 Oct 24. doi: 10.3892/ijo.2018.4605.
    PubMed     Abstract available

  62. TAN Y, Wang Q, Xie Y, Qiao X, et al
    Identification of FOXM1 as a specific marker for triplenegative breast cancer.
    Int J Oncol. 2018 Oct 19. doi: 10.3892/ijo.2018.4598.
    PubMed     Abstract available

  63. GAO Y, Liu H, Wang H, Hu H, et al
    Baicalin inhibits breast cancer development via inhibiting IkB kinase activation in vitro and in vivo.
    Int J Oncol. 2018 Oct 12. doi: 10.3892/ijo.2018.4594.
    PubMed     Abstract available

  64. LU H, Chen J, Luo Y, Xu H, et al
    Curcolonol suppresses the motility of breast cancer cells by inhibiting LIM kinase 1 to downregulate cofilin 1 phosphorylation.
    Int J Oncol. 2018 Oct 10. doi: 10.3892/ijo.2018.4592.
    PubMed     Abstract available

  65. SHAO YC, Nie XC, Song GQ, Wei Y, et al
    Prognostic value of DKK2 from the Dickkopf family in human breast cancer.
    Int J Oncol. 2018 Oct 9. doi: 10.3892/ijo.2018.4588.
    PubMed     Abstract available

    September 2018
  66. ZHAO Y, Pang W, Yang N, Hao L, et al
    MicroRNA-511 inhibits malignant behaviors of breast cancer by directly targeting SOX9 and regulating the PI3K/Akt pathway.
    Int J Oncol. 2018 Sep 27. doi: 10.3892/ijo.2018.4576.
    PubMed     Abstract available

  67. SUN L, He M, Xu N, Xu DH, et al
    Regulation of RAB22A by mir-193b inhibits breast cancer growth and metastasis mediated by exosomes.
    Int J Oncol. 2018 Sep 25. doi: 10.3892/ijo.2018.4571.
    PubMed     Abstract available

    August 2018
  68. LI B, Chen P, Wang J, Wang L, et al
    MicroRNA-1254 exerts oncogenic effects by directly targeting RASSF9 in human breast cancer.
    Int J Oncol. 2018 Aug 21. doi: 10.3892/ijo.2018.4530.
    PubMed     Abstract available

  69. GAO Z, Wang H, Li H, Li M, et al
    Long non-coding RNA CASC2 inhibits breast cancer cell growth and metastasis through the regulation of the miR-96-5p/SYVN1 pathway.
    Int J Oncol. 2018 Aug 13. doi: 10.3892/ijo.2018.4522.
    PubMed     Abstract available

  70. LUCAS J, Hsieh TC, Halicka HD, Darzynkiewicz Z, et al
    Upregulation of PDL1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300mediated NFkappaB signaling.
    Int J Oncol. 2018 Aug 1. doi: 10.3892/ijo.2018.4512.
    PubMed     Abstract available

    July 2018
  71. LIU J, Li X, Wang M, Xiao G, et al
    A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Int J Oncol. 2018 Jul 19. doi: 10.3892/ijo.2018.4492.
    PubMed     Abstract available

  72. LIU F, Sang M, Meng L, Gu L, et al
    miR92b promotes autophagy and suppresses viability and invasion in breast cancer by targeting EZH2.
    Int J Oncol. 2018 Jul 18. doi: 10.3892/ijo.2018.4486.
    PubMed     Abstract available

  73. LIU Y, Dong Y, Zhao L, Su L, et al
    Circular RNAMTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis.
    Int J Oncol. 2018 Jul 17. doi: 10.3892/ijo.2018.4485.
    PubMed     Abstract available

  74. WANG Y, Yan L, Zhang L, Xu H, et al
    NT21MP negatively regulates paclitaxel-resistant cells by targeting miR1553p and miR155-5p via the CXCR4 pathway in breast cancer.
    Int J Oncol. 2018 Jul 9. doi: 10.3892/ijo.2018.4477.
    PubMed     Abstract available

  75. WU CL, Zhang SM, Lin L, Gao SS, et al
    BECN1-knockout impairs tumor growth, migration and invasion by suppressing the cell cycle and partially suppressing the epithelial-mesenchymal transition of human triple-negative breast cancer cells.
    Int J Oncol. 2018 Jul 5. doi: 10.3892/ijo.2018.4472.
    PubMed     Abstract available

  76. JIMENEZ-MORALES S, Perez-Amado CJ, Langley E, Hidalgo-Miranda A, et al
    Overview of mitochondrial germline variants and mutations in human disease: Focus on breast cancer (Review).
    Int J Oncol. 2018 Jul 4. doi: 10.3892/ijo.2018.4468.
    PubMed     Abstract available

  77. DONG H, Wang W, Chen R, Zhang Y, et al
    Exosome-mediated transfer of lncRNASNHG14 promotes trastuzumab chemoresistance in breast cancer.
    Int J Oncol. 2018 Jul 3. doi: 10.3892/ijo.2018.4467.
    PubMed     Abstract available

  78. FRISTIOHADY A, Milovanovic D, Krieger S, Huttary N, et al
    12(S)-HETE induces lymph endothelial cell retraction in vitro by upregulation of SOX18.
    Int J Oncol. 2018;53:307-316.
    PubMed     Abstract available

    June 2018
  79. HAN W, Cao F, Gao XJ, Wang HB, et al
    ZIC1 acts a tumor suppressor in breast cancer by targeting survivin.
    Int J Oncol. 2018 Jun 21. doi: 10.3892/ijo.2018.4450.
    PubMed     Abstract available

  80. NOWAK A, Dziegiel P
    Implications of nestin in breast cancer pathogenesis (Review).
    Int J Oncol. 2018 Jun 14. doi: 10.3892/ijo.2018.4441.
    PubMed     Abstract available

  81. CARLISLE SM, Hein DW
    Retrospective analysis of estrogen receptor 1 and Nacetyltransferase gene expression in normal breast tissue, primary breast tumors, and established breast cancer cell lines.
    Int J Oncol. 2018 Jun 11. doi: 10.3892/ijo.2018.4436.
    PubMed     Abstract available

    May 2018
  82. CHENG CC, Shi LH, Wang XJ, Wang SX, et al
    Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Int J Oncol. 2018 May 8. doi: 10.3892/ijo.2018.4399.
    PubMed     Abstract available

  83. KIM JY, Kim JC, Lee JY, Park MJ, et al
    Oct4 suppresses IRinduced premature senescence in breast cancer cells through STAT3- and NFkappaB-mediated IL24 production.
    Int J Oncol. 2018 May 2. doi: 10.3892/ijo.2018.4391.
    PubMed     Abstract available

    April 2018
  84. TAN Y, Zhou G, Wang X, Chen W, et al
    USP18 promotes breast cancer growth by upregulating EGFR and activating the AKT/Skp2 pathway.
    Int J Oncol. 2018 Apr 30. doi: 10.3892/ijo.2018.4387.
    PubMed     Abstract available

  85. ZHAO Y, Onda K, Yuan B, Tanaka S, et al
    Arsenic disulfideinduced apoptosis and its potential mechanism in two and threedimensionally cultured human breast cancer MCF7 cells.
    Int J Oncol. 2018 Apr 4. doi: 10.3892/ijo.2018.4357.
    PubMed     Abstract available

    March 2018
  86. ZHAO FQ, Misra Y, Li DB, Wadsworth MP, et al
    Differential expression of Oct3/4 in human breast cancer and normal tissues.
    Int J Oncol. 2018 Mar 29. doi: 10.3892/ijo.2018.4341.
    PubMed     Abstract available

  87. XIONG DD, Chen H, He RQ, Lan AH, et al
    MicroRNA-671-3p inhibits the development of breast cancer: A study based on in vitro experiments, in-house quantitative polymerase chain reaction and bioinformatics analysis.
    Int J Oncol. 2018 Mar 28. doi: 10.3892/ijo.2018.4339.
    PubMed     Abstract available

  88. COLIN C, Meyer M, Cerella C, Kleinclauss A, et al
    Biotinylation enhances the anticancer effects of 15dPGJ2 against breast cancer cells.
    Int J Oncol. 2018 Mar 28. doi: 10.3892/ijo.2018.4338.
    PubMed     Abstract available

  89. BUSCHMANN D, Gonzalez R, Kirchner B, Mazzone C, et al
    Glucocorticoid receptor overexpression slightly shifts microRNA expression patterns in triple-negative breast cancer.
    Int J Oncol. 2018 Mar 27. doi: 10.3892/ijo.2018.4336.
    PubMed     Abstract available

  90. LI Y, Zhang Y, Liu X, Wang M, et al
    Lutein inhibits proliferation, invasion and migration of hypoxic breast cancer cells via downregulation of HES1.
    Int J Oncol. 2018 Mar 23. doi: 10.3892/ijo.2018.4332.
    PubMed     Abstract available

  91. WU T, Song H, Xie D, Zhao B, et al
    Silencing of ASPP2 promotes the proliferation, migration and invasion of triple-negative breast cancer cells via the PI3K/AKT pathway.
    Int J Oncol. 2018 Mar 20. doi: 10.3892/ijo.2018.4331.
    PubMed     Abstract available

  92. BEBEROK A, Wrzesniok D, Rok J, Rzepka Z, et al
    Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53/Bax/Bcl-2 signaling pathway.
    Int J Oncol. 2018 Mar 8. doi: 10.3892/ijo.2018.4310.
    PubMed     Abstract available

  93. DI D, Chen L, Guo Y, Wang L, et al
    BCSC-1 suppresses human breast cancer metastasis by inhibiting NF-kappaB signaling.
    Int J Oncol. 2018 Mar 7. doi: 10.3892/ijo.2018.4309.
    PubMed     Abstract available

  94. MIYAGAWA Y, Matsushita Y, Suzuki H, Komatsu M, et al
    Frequent downregulation of LRRC26 by epigenetic alterations is involved in the malignant progression of triple-negative breast cancer.
    Int J Oncol. 2018 Mar 5. doi: 10.3892/ijo.2018.4301.
    PubMed     Abstract available

  95. WANG H, Xiao Y, Wu L, Ma D, et al
    Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-000911/miR-449a pathway in breast carcinogenesis.
    Int J Oncol. 2018;52:743-754.
    PubMed     Abstract available

    February 2018
  96. CASTELLANOS-ESPARZA YC, Wu S, Huang L, Buquet C, et al
    Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells.
    Int J Oncol. 2018 Feb 9. doi: 10.3892/ijo.2018.4272.
    PubMed     Abstract available

  97. MAXWELL T, Lee KS, Kim S, Nam KS, et al
    Arctigenin inhibits the activation of the mTOR pathway, resulting in autophagic cell death and decreased ER expression in ER-positive human breast cancer cells.
    Int J Oncol. 2018 Feb 9. doi: 10.3892/ijo.2018.4271.
    PubMed     Abstract available

  98. HAN Y, Fan S, Qin T, Yang J, et al
    Role of autophagy in breast cancer and breast cancer stem cells (Review).
    Int J Oncol. 2018 Feb 8. doi: 10.3892/ijo.2018.4270.
    PubMed     Abstract available

  99. YEN MC, Huang YC, Kan JY, Kuo PL, et al
    S100B expression in breast cancer as a predictive marker for cancer metastasis.
    Int J Oncol. 2018;52:433-440.
    PubMed     Abstract available

  100. NOWAK A, Grzegrzolka J, Kmiecik A, Piotrowska A, et al
    Role of nestin expression in angiogenesis and breast cancer progression.
    Int J Oncol. 2018;52:527-535.
    PubMed     Abstract available

    January 2018
  101. PENG F, Li Q, Sun JY, Luo Y, et al
    PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis.
    Int J Oncol. 2018 Jan 30. doi: 10.3892/ijo.2018.4257.
    PubMed     Abstract available

  102. ZHONG R, Liang B, Xin R, Zhu X, et al
    Deoxycytidine kinase participates in the regulation of radiation-induced autophagy and apoptosis in breast cancer cells.
    Int J Oncol. 2018 Jan 22. doi: 10.3892/ijo.2018.4250.
    PubMed     Abstract available

  103. YOU KS, Yi YW, Kwak SJ, Seong YS, et al
    Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    Int J Oncol. 2018 Jan 15. doi: 10.3892/ijo.2018.4244.
    PubMed     Abstract available

  104. ABSMAIER M, Napieralski R, Schuster T, Aubele M, et al
    PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
    Int J Oncol. 2018 Jan 8. doi: 10.3892/ijo.2018.4241.
    PubMed     Abstract available

  105. CHANG LC, Hsieh MT, Yang JS, Lu CC, et al
    Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study.
    Int J Oncol. 2018;52:67-76.
    PubMed     Abstract available

  106. WANG Y, Yu X, Song H, Feng D, et al
    The STAT-ROS cycle extends IFNinduced cancer cell apoptosis.
    Int J Oncol. 2018;52:305-313.
    PubMed     Abstract available

    November 2017
  107. ALONSO-GONZALEZ C, Menendez-Menendez J, Gonzalez-Gonzalez A, Gonzalez A, et al
    Melatonin enhances the apoptotic effects and modulates the changes in gene expression induced by docetaxel in MCF7 human breast cancer cells.
    Int J Oncol. 2017 Nov 28. doi: 10.3892/ijo.2017.4213.
    PubMed     Abstract available

  108. SONNENBLICK A, Salgado R, Brohee S, Zahavi T, et al
    p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.
    Int J Oncol. 2017 Nov 27. doi: 10.3892/ijo.2017.4212.
    PubMed     Abstract available

    October 2017
  109. RAMAN V, Fuentes Lorenzo JL, Stashenko EE, Levy M, et al
    Lippia origanoides extract induces cell cycle arrest and apoptosis and suppresses NF-kappaB signaling in triple-negative breast cancer cells.
    Int J Oncol. 2017 Oct 19. doi: 10.3892/ijo.2017.4169.
    PubMed     Abstract available

  110. BORAH N, Gunawardana S, Torres H, McDonnell S, et al
    5,6,7,3',4',5'-Hexamethoxyflavone inhibits growth of triple-negative breast cancer cells via suppression of MAPK and Akt signaling pathways and arresting cell cycle.
    Int J Oncol. 2017 Oct 13. doi: 10.3892/ijo.2017.4157.
    PubMed     Abstract available

  111. RATAJCZAK-WIELGOMAS K, Grzegrzolka J, Piotrowska A, Matkowski R, et al
    Expression of periostin in breast cancer cells.
    Int J Oncol. 2017;51:1300-1310.
    PubMed     Abstract available

  112. YIN H, Zhu Q, Liu M, Tu G, et al
    GPER promotes tamoxifen-resistance in ER+ breast cancer cells by reduced Bim proteins through MAPK/Erk-TRIM2 signaling axis.
    Int J Oncol. 2017;51:1191-1198.
    PubMed     Abstract available

  113. PHILLIPS SL, Williams CB, Zambrano JN, Williams CJ, et al
    Connexin 43 in the development and progression of breast cancer: What's the connection? (Review).
    Int J Oncol. 2017;51:1005-1013.
    PubMed     Abstract available

    September 2017
  114. YANG L, Li Y, Shen E, Cao F, et al
    NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
    Int J Oncol. 2017 Sep 21. doi: 10.3892/ijo.2017.4130.
    PubMed     Abstract available

  115. ESPINOZA-SANCHEZ NA, Vadillo E, Balandran JC, Monroy-Garcia A, et al
    Evidence of lateral transmission of aggressive features between different types of breast cancer cells.
    Int J Oncol. 2017 Sep 19. doi: 10.3892/ijo.2017.4128.
    PubMed     Abstract available

  116. CALAF GM, Roy D
    Metastatic genes targeted by an antioxidant in an established radiation- and estrogen-breast cancer model.
    Int J Oncol. 2017 Sep 14. doi: 10.3892/ijo.2017.4125.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.